Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 15.38 percent increase over losses of $(0.13) per share from the same period last year.